Skip to main content

CONnective TIssue CAncers NETwork to integrate European Experience in Adults and Children

Objective

Connective tissue cancers and more specifically sarcomas, GIST, aggressive fibromatosis and hamartomas, are uncommon cancers with an incidence below 2/100 000/year in the EU affecting children, young adults and adults. At a national level, the limited num ber of cases (about 7-10 000 in Europe each year) does notallow Europe to have a critical mass of researchers and the supporting environment to progress in disease understanding and management and have access to new drugs and treatments. Europe has prove n with research made on GIST or through the EORTC-STBSG group that gathering workforces can achieve significant progress. CONTICANET will create the critical mass of key stakeholders to overcome the current difficulties in terms of lack of data and data fragmentation, mobility of researchers, heterogeneity of methodologies and legislations. CONTICANET will 1) start by providing the required environment for developing joint research activities through the development of standard operating procedures, di stributed databases, tissue banks and harmonisation of research projects, then 2) provide the infrastructure to test several drug candidates and perform European wide clinical trials while implementing a federated research policy to 3) further lead to an integrated sustainable structure a European research foundation able to support integrated research actions and make available new treatments. Involving 20 partners major comprehensive cancer centres, academia and private companies over 5 years, CONTICAN ET will gather the critical mass of resources and knowledge in the understanding, diagnosis and management of connective tissue cancers, opening new therapeutic options. CONTICANET will spread excellence in several directions: enlarging the network with ot her academic and private organisations; developing relationship with EMEA, health authorities and insurances; supporting and collaborating with patients through advocacy groups or cancer leagues.

Call for proposal

FP6-2004-LIFESCIHEALTH-5
See other projects for this call

Coordinator

UNIVERSITÉ CLAUDE BERNARD LYON 1
Address
43 Bd Du 11 Novembre 1918
Lyon
France

Participants (20)

ALLGEMEINES KRANKENHAUS ST GEORG
Germany
Address
Lohmühlenstr. 5
Hamburg
NATIONAL UNIVERSITY OF IRELAND, CORK - UNIVERSITY COLLEGE CORK
Ireland
Address
Western Road
Cork
ERASMUS MEDISCH CENTRUM
Netherlands
Address
Dr.molenwaterplein 40
Rotterdam
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
United Kingdom
Address
123 Old Brompton Road
London
INSTITUT GUSTAVE ROUSSY
France
Address
39 Rue Camille Desmoulins
Villejuif
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
Italy
Address
Via G. Venezian 1
Milano
IPSOGEN SAS
France
Address
Luminy Biotech Entreprises, Case 923, 163 Avenue De Luminy
Marseille
INSTITUTE OF ONCOLOGY LJUBLJANA
Slovenia
Address
Zaloska 2
Ljubljana
PHARMAMAR SOCIEDAD ANONIMA SOCIEDAD UNIPERSONAL
Spain
Address
Poligono Industrial La Mina, Avda. De Los Reyes, 1
Colmenar Viejo, Madrid
SANOFI-AVENTIS
France
Address
174, Avenue De France
Paris
KATHOLIEKE UNIVERSITEIT LEUVEN
Belgium
Address
Oude Markt 13
Leuven
CENTRE HOSPITALO-UNIVERSITAIRE SAINT LOUIS
France
Address
1, Avenue Claude Vellefaux
Paris
ARTTIC
France
Address
58 A Rue Du Dessous Des Berges
Paris
EZUS LYON 1
France
Address
43 Bd Du 11 Novembre 1918 - Bâtiment L'atrium
Villeurbanne
INSTITUT CURIE
France
Address
Rue D'ulm
Paris
ECOLE NORMALE SUPÉRIEURE DE CACHAN
France
Address
61, Avenue Du Président Wilson
Cachan
INSTITUT BERGONIÉ
France
Address
229, Cours De L'argonne
Bordeaux
LYON 1 INGÉNIERIE
France
Address
43 Boulevard Du 11 Novembre 1918
Villeurbanne
RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
Germany
Address
Seminarstr.2
Heidelberg
UNIVERSITÀ DEGLI STUDI DI PADOVA
Italy
Address
Via Viii Febbraio
Padova